Hennion & Walsh Asset Management Inc. Cuts Position in Krystal Biotech, Inc. (NASDAQ:KRYS)

Hennion & Walsh Asset Management Inc. decreased its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 25.4% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 10,205 shares of the company's stock after selling 3,473 shares during the quarter. Hennion & Walsh Asset Management Inc.'s holdings in Krystal Biotech were worth $1,840,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. FMR LLC increased its stake in Krystal Biotech by 0.5% during the fourth quarter. FMR LLC now owns 4,314,014 shares of the company's stock worth $675,833,000 after purchasing an additional 21,133 shares during the period. Vanguard Group Inc. increased its stake in Krystal Biotech by 1.0% during the fourth quarter. Vanguard Group Inc. now owns 2,878,451 shares of the company's stock worth $450,938,000 after purchasing an additional 28,707 shares during the period. Avoro Capital Advisors LLC increased its stake in Krystal Biotech by 0.3% during the fourth quarter. Avoro Capital Advisors LLC now owns 2,628,822 shares of the company's stock worth $411,831,000 after purchasing an additional 6,600 shares during the period. Hood River Capital Management LLC increased its stake in shares of Krystal Biotech by 2.1% during the fourth quarter. Hood River Capital Management LLC now owns 512,726 shares of the company's stock worth $80,324,000 after buying an additional 10,622 shares during the period. Finally, Price T Rowe Associates Inc. MD increased its stake in shares of Krystal Biotech by 16.2% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 509,459 shares of the company's stock worth $79,812,000 after buying an additional 71,200 shares during the period. 86.29% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the company's stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the completion of the sale, the insider now owns 1,463,711 shares in the company, valued at $260,233,178.69. This represents a 1.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 13.70% of the company's stock.

Krystal Biotech Price Performance

Shares of KRYS stock traded down $0.86 during trading hours on Monday, hitting $136.08. The stock had a trading volume of 342,345 shares, compared to its average volume of 312,163. The firm has a market capitalization of $3.93 billion, a PE ratio of 45.51 and a beta of 0.65. Krystal Biotech, Inc. has a twelve month low of $122.80 and a twelve month high of $219.34. The stock's 50 day moving average is $149.85 and its 200 day moving average is $162.99.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported $1.20 earnings per share for the quarter, missing the consensus estimate of $1.38 by ($0.18). The firm had revenue of $88.18 million during the quarter, compared to analyst estimates of $98.66 million. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. As a group, equities analysts predict that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

Wall Street Analysts Forecast Growth

KRYS has been the topic of a number of recent research reports. HC Wainwright restated a "buy" rating and set a $240.00 target price on shares of Krystal Biotech in a research note on Tuesday, May 6th. Guggenheim cut their target price on shares of Krystal Biotech from $195.00 to $189.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. Citigroup cut their target price on shares of Krystal Biotech from $215.00 to $155.00 and set a "neutral" rating on the stock in a research note on Friday, May 16th. Jefferies Financial Group assumed coverage on shares of Krystal Biotech in a research note on Wednesday, March 5th. They set a "buy" rating and a $245.00 target price on the stock. Finally, Chardan Capital reaffirmed a "buy" rating and issued a $219.00 price target on shares of Krystal Biotech in a report on Wednesday, May 7th. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Krystal Biotech presently has an average rating of "Buy" and a consensus price target of $211.13.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).